Side-by-side · Research reference
Follistatin-344vsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED4/58 cited
BAnimal-StrongAUTO-DRAFTED13/39 cited
Follistatin-344
Myostatin/Activin Antagonist · Research Use
15–25%FST/MSTN ratio ↑
344 AACirculating isoform
ResearchPhase status
Research · No approved protocol
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
Follistatin-344
KPV
Primary target
Myostatin (MSTN/GDF-8) and Activin A
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
FST-344 binds MSTN/Activin → prevents ActRIIB receptor engagement → disinhibits muscle anabolism
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Elevated follistatin/myostatin ratio, increased muscle protein synthesis, attenuated muscle atrophy signalingJeong 2026
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
Yes — indirect antagonist, preserves endogenous regulation
No melanocortin receptor binding
Origin
Endogenous glycoprotein, 344-AA isoform lacking heparin-binding domain (vs FST-315)
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
Not documented in available trials (endogenous protein)
—
02Dosage Protocols
Parameter
Follistatin-344
KPV
Clinical protocol
None — no approved dosing regimen
Follistatin-344 measured as endogenous biomarker, not administered exogenously in cited trials.
—
Research context
Endogenous modulation via exercise + nutrition
Resistance training + EAA intake elevated FST/MSTN ratio by 15–25% in 12-week RCT (older women).
—
Evidence basis
Human observational / biomarker studies
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Half-life
Not established
Circulating isoform; lacks tissue-binding domain of FST-315.
Hours (estimated; rapid tissue uptake)
Frequency
—
Daily or 2–3× per week
Lower / starter dose
—
100 mcg / day
Duration
—
4–8 weeks per cycle
Reconstitution
—
Bacteriostatic water (SQ form)
Timing
—
No specific time; often taken with / before meals (oral)
03Metabolic / Fat Loss Evidence
Parameter
Follistatin-344
KPV
Primary target
Muscle mass preservation, not direct lipolysis
—
Indirect fat effect
Increased lean mass → elevated resting metabolic rate
Not primary mechanism. Muscle-sparing during deficit.
—
Clinical evidence
Lorcaserin trial (6 mo) showed no MAFI axis changes during fat lossRamirez-Cisneros 2026
Suggests follistatin not primary driver of fat loss in weight-reduction interventions.
—
GLP-1RA studies
Liraglutide (35 days) — no significant MAFI axis modulation despite fat/lean changes
—
04Side Effects & Safety
Parameter
Follistatin-344
KPV
Clinical safety data
None — no human exogenous administration trials in literature
—
Theoretical risks
Excessive myostatin inhibition → muscle overgrowth, impaired glucose tolerance
Based on myostatin-null animal models and clinical myostatin inhibitor trials.
—
Endogenous elevation (exercise)
No adverse effects reported in 12-week resistance + EAA trials
—
Cancer risk (theoretical)
Myostatin inhibition may promote tumor growth in malignancy (preclinical data)
—
Regulatory status
Not approved for human use — research peptide only
—
Injection site reaction
—
Mild irritation
GI symptoms
—
Rare nausea (oral form)
Long-term safety
—
Limited human data
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
Follistatin-344
- ·Active malignancy
- ·No approved protocol — research use only
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
Follistatin-344
- ·Insulin resistance / Type 2 diabetes (monitor glucose)
- ·Pregnancy / lactation (unknown safety profile)
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
Follistatin-344
KPV
1. Regulatory status
Follistatin-344 is not approved for human administration. All cited studies measure endogenous serum follistatin as a biomarker, not as an exogenous therapeutic agent.
Add 1 mL bacteriostatic water to vial per labelling.
2. Endogenous modulation
Resistance exercise combined with essential amino acid (EAA) supplementation elevated the follistatin/myostatin ratio by 15–25% in 12-week randomized trials. Protein intake (1.2–1.5 g/kg/day) synergizes with training to upregulate endogenous follistatin.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Measurement context
Serum follistatin and follistatin/myostatin ratio are used diagnostically in sarcopenia screening and as biomarkers of muscle anabolic balance in clinical trials.
Morning preferred; oral form taken with / before meals.
4. Research consideration
Gene therapy and recombinant follistatin delivery are under preclinical investigation for muscular dystrophy and sarcopenia. No human safety or efficacy data for exogenous FST-344 administration.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
—
29–31G insulin syringe (SQ form).
06Stack Synergy
Follistatin-344
+ BPC-157
Multi-pathwayFollistatin-344 (myostatin antagonist) and BPC-157 (tissue repair peptide) address complementary pathways in muscle recovery. FST-344 promotes muscle protein synthesis by disinhibiting myostatin signaling, while BPC-157 accelerates healing of tendons, ligaments, and microtears via angiogenesis and collagen synthesis. Combined, they may support both hypertrophy and structural repair during high-volume training or injury recovery.
- Follistatin-344
- No approved protocol — endogenous modulation via resistance exercise + EAA
- BPC-157
- 250–500 mcg SQ · twice daily · near injury site or systemic
- Duration
- 4–8 weeks
- Primary benefit
- Muscle hypertrophy + accelerated soft tissue repair
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) promotes cell migration, angiogenesis, and anti-inflammatory signaling in muscle and connective tissue. Follistatin-344's anabolic signaling may synergize with TB-500's regenerative effects during muscle damage or overtraining, particularly in older adults where both myostatin inhibition and tissue repair are rate-limiting.
- Follistatin-344
- Endogenous upregulation (resistance training + protein)
- TB-500
- 2–5 mg SQ · twice weekly · loading phase 4 weeks, then maintenance
- Frequency
- Twice weekly TB-500, daily training stimulus for FST
- Primary benefit
- Enhanced recovery, reduced inflammation, muscle growth support
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions